News / 

Sanofi, Merck file for US FDA approval of cervical cancer vaccine

Save Story

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

PARIS (AFX) - Sanofi-Pasteur MSD, the vaccine producer jointly owned by Sanofi-Aventis and Merck & Co, said it has filed for approval from the US Food and Drug Administration of its experimental vaccine against cervical cancer, Gardasil.

The company will file for approval in Europe and Australia before the end of this year.

Gardasil was developed by Merck, and aims to protect against four types of viruses that are the main causes of cervical cancer, which is the second most-deadly form of cancer for women aged 15 to 44 after breast cancer.


COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and the AFX Financial News logo are registered trademarks of AFX News Limited

Copyright 2005 AFX News Limited. All Rights Reserved.

Most recent News stories


Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the Trending 5.
By subscribing, you acknowledge and agree to's Terms of Use and Privacy Policy.

KSL Weather Forecast